DK4284387T3 - Nad-forstærkelsesterapi til parkinsons sygdom - Google Patents
Nad-forstærkelsesterapi til parkinsons sygdom Download PDFInfo
- Publication number
- DK4284387T3 DK4284387T3 DK22740800.2T DK22740800T DK4284387T3 DK 4284387 T3 DK4284387 T3 DK 4284387T3 DK 22740800 T DK22740800 T DK 22740800T DK 4284387 T3 DK4284387 T3 DK 4284387T3
- Authority
- DK
- Denmark
- Prior art keywords
- nad
- parkinson
- disease
- enhancement therapy
- enhancement
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2109138.4A GB202109138D0 (en) | 2021-06-24 | 2021-06-24 | NAD-augmentation Therapy for parkinson's disease |
| GBGB2200883.3A GB202200883D0 (en) | 2021-06-24 | 2022-01-24 | Nad-augmentation therapy for parkinson's disease |
| GR20220100277 | 2022-03-29 | ||
| PCT/EP2022/067412 WO2022269066A1 (en) | 2021-06-24 | 2022-06-24 | Nad-augmentation therapy for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4284387T3 true DK4284387T3 (da) | 2024-09-02 |
Family
ID=82492391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22740800.2T DK4284387T3 (da) | 2021-06-24 | 2022-06-24 | Nad-forstærkelsesterapi til parkinsons sygdom |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240366648A1 (da) |
| EP (1) | EP4284387B1 (da) |
| JP (1) | JP2024524991A (da) |
| AU (1) | AU2022299351B2 (da) |
| CA (1) | CA3222399A1 (da) |
| DK (1) | DK4284387T3 (da) |
| ES (1) | ES2986075T3 (da) |
| FI (1) | FI4284387T3 (da) |
| PL (1) | PL4284387T3 (da) |
| WO (1) | WO2022269066A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250275995A1 (en) * | 2022-04-26 | 2025-09-04 | Vestlandets Innovasjonsselskap As (Vis) | Nicotinamide riboside dosage regimen for treating parkinson's disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0331620B1 (de) | 1988-03-01 | 1993-08-11 | Birkmayer, Walther, Prof. Dr. | Mittel zur Behandlung des Parkinson-Syndroms |
| EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| AU2017316614B2 (en) * | 2016-08-22 | 2023-06-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
| WO2020257283A1 (en) * | 2019-06-18 | 2020-12-24 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| WO2022028678A1 (en) * | 2020-08-04 | 2022-02-10 | Scandibio Therapeutics Ab | Substances for treatment of neurological disorders |
-
2022
- 2022-06-24 FI FIEP22740800.2T patent/FI4284387T3/fi active
- 2022-06-24 JP JP2023579260A patent/JP2024524991A/ja active Pending
- 2022-06-24 PL PL22740800.2T patent/PL4284387T3/pl unknown
- 2022-06-24 DK DK22740800.2T patent/DK4284387T3/da active
- 2022-06-24 ES ES22740800T patent/ES2986075T3/es active Active
- 2022-06-24 WO PCT/EP2022/067412 patent/WO2022269066A1/en not_active Ceased
- 2022-06-24 AU AU2022299351A patent/AU2022299351B2/en active Active
- 2022-06-24 US US18/573,963 patent/US20240366648A1/en active Pending
- 2022-06-24 CA CA3222399A patent/CA3222399A1/en active Pending
- 2022-06-24 EP EP22740800.2A patent/EP4284387B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4284387A1 (en) | 2023-12-06 |
| FI4284387T3 (fi) | 2024-08-20 |
| ES2986075T3 (es) | 2024-11-08 |
| JP2024524991A (ja) | 2024-07-09 |
| US20240366648A1 (en) | 2024-11-07 |
| CA3222399A1 (en) | 2022-12-29 |
| AU2022299351B2 (en) | 2025-01-30 |
| EP4284387B1 (en) | 2024-07-31 |
| WO2022269066A1 (en) | 2022-12-29 |
| AU2022299351A1 (en) | 2024-01-04 |
| PL4284387T3 (pl) | 2024-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
| DK3906066T5 (da) | Geneterapikonstruktioner til behandling af wilsons sygdom | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| EA201200507A1 (ru) | Применение активаторов никотинового ацетилхолинового рецептора альфа 7 | |
| IL280315A (en) | Methods of treatment and prevention of alzheimer's disease | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| IL309468A (en) | Biomarkers for alzheimer's disease treatment | |
| IL278813A (en) | Gene therapy for Alzheimer's disease | |
| IL292148A (en) | Gene therapy for Alzheimer's disease | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| DOP2018000103A (es) | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson. | |
| DK4284387T3 (da) | Nad-forstærkelsesterapi til parkinsons sygdom | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| GB202016425D0 (en) | Treatment regimens for parkinson's disease | |
| IL280326A (en) | Small RNA contracts for Alzheimer's disease | |
| MX2018015397A (es) | Co-cristales de benzoato de sodio y sus usos. | |
| EP3429569A4 (en) | METHOD FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY PARNY SYNTHESIS | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| BR112014024736A2 (pt) | antagonista receptor de h3 para uso no tratamento de doença de alzheimer | |
| BR112022008113A2 (pt) | Formas sólidas de um modulador de receptor s1p | |
| EA200701584A1 (ru) | Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения | |
| EP3981469A4 (en) | THERAPEUTIC FOR GOUT OR HYPERURICEMIA |